Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03047395) enrolled 2,170 people who were all given risankizumab 150 mg. Of those who started, 1,601 completed the study and 569 did not finish. The trial's main focus was on tracking and recording adverse events — that is, any unwanted or unexpected medical occurrences that happened during the study, whether or not they were thought to be related to the medication. The reported data shows two categories of adverse events were counted. A serious adverse event was defined as something that caused death, was life-threatening, required a hospital stay, caused lasting disability, or was otherwise judged to be a significant medical concern. A non-serious adverse event covered any other unwanted medical occurrence. According to the figures submitted, 435 participants were reported to have experienced serious adverse events, and 1,215 participants were reported to have experienced non-serious adverse events during the study period. No other outcome measures were included in the submitted results data. It is worth noting that recording adverse events is a standard part of clinical trials and does not on its own tell us whether a treatment is beneficial or harmful — it simply documents what medical events occurred and how often. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40728772) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a history of moderate to severe chronic plaque psoriasis and have already completed one of the specific earlier studies linked to this trial.
- Your doctor believes you are a suitable candidate to continue receiving the study drug (risankizumab) on an ongoing basis.
- If you are a woman who could become pregnant, you must have a negative pregnancy test at the start of the study.
- If you are a woman, you must either be past menopause, have had a permanent surgical procedure to prevent pregnancy, or agree to use at least one approved method of birth control from the start of the study until at least 20 weeks after your last dose.
- You must have read, understood, and signed a consent form agreeing to take part in the study before joining.
Who may not be able to join:
- You left the previous linked study early for any reason.
- You developed a different type of psoriasis (such as guttate, erythrodermic, pustular, or drug-induced psoriasis) during the previous study.
- You are taking a medication that is not allowed in this study or that could interfere with the study results, as decided by your doctor.
- You have a current or past serious health condition, surgery (such as an organ transplant), abnormal test result, or other medical finding — beyond psoriasis — that your doctor believes could affect your safety or your ability to follow the study rules (confirm with trial site).
- You have previously taken part in this specific study before.
- You are pregnant, breastfeeding, or planning to become pregnant during the study or within 20 weeks after your last dose of the study drug.
- More than 8 weeks have passed since you completed your final visit in the previous linked study.
- Your doctor has decided for any reason that you are not a suitable candidate or would not be able to follow the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants With Serious Adverse Events and Non-Serious Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.